Document Detail


Oral versus combination mesalazine therapy in active ulcerative colitis: a double-blind, double-dummy, randomized multicentre study.
MedLine Citation:
PMID:  11148445     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Oral and topical mesalazine formulations are effective in active ulcerative colitis, but little is known on the efficacy of combined treatment. AIM: To compare the efficacy of oral mesalazine vs. combined oral and topical mesalazine in mildly to moderately active ulcerative colitis. METHODS: Patients with mildly to moderately active ulcerative colitis (Clinical Activity Index, CAI 4-12) were identified at 15 participating centres. They were randomized to receive either mesalazine 4 g orally plus placebo enema, or mesalazine 2 g orally plus mesalazine 2 g rectally as a liquid enema for 6 weeks. The rate of clinical remission (CAI < 4) or clinical remission/improvement (reduction of CAI of 50% from baseline) at 6 weeks and time to clinical remission/improvement were primary end-points; the rate of endoscopic remission was a secondary end-point. RESULTS: 67 patients were assigned to oral treatment and 63 to combined treatment. One patient in the oral group and 2 in the combined group discontinued the treatment due to adverse events. Following an intention-to-treat analysis, the rate of clinical remission was 82% for oral treatment and 87% for combined treatment (P=0.56); the mean time to remission 22.2 and 20.2 days, respectively (P=0.29); the rate of clinical remission/improvement and the rate of endoscopic remission were 85% and 91% (P=0.503) and 58% and 71% (P=0.21), respectively. CONCLUSIONS: In patients with mild active ulcerative colitis, mesalazine 4 g orally and 2 g orally plus 2 g enema are equally effective in inducing disease remission.
Authors:
M Vecchi; G Meucci; P Gionchetti; M Beltrami; P Di Maurizio ; L Beretta; E Ganio; P Usai; M Campieri; G Fornaciari; R de Franchis
Related Documents :
2356675 - Recurrences after highly selective vagotomy in refractory and non-refractory duodenal u...
7134875 - Seasonal occurrence of abdominal pain and endoscopic findings in patients with gastric ...
2191425 - Role of rectal formulations: suppositories.
15754865 - Three failures of direct suggestion in psychogenic dermatitis followed by successful in...
23120595 - Use of autogenic and allogenic malleus in tympanic membrane to footplate assembly - lon...
22301335 - Endovascular treatment of descending thoracic aortic disease: single-center, 15-year ex...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  15     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2001 Feb 
Date Detail:
Created Date:  2001-01-26     Completed Date:  2001-02-22     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  251-6     Citation Subset:  IM    
Affiliation:
Gastroenterology and Gastrointestinal Endoscopy Service, Department of Internal Medicine, IRCCS Ospedale Policlinico, Milan, Italy. gastro@polic.cilea.it
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Oral
Administration, Topical
Adolescent
Adult
Aged
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage*,  therapeutic use
Colitis, Ulcerative / drug therapy*
Double-Blind Method
Female
Humans
Male
Mesalamine / administration & dosage*,  therapeutic use
Middle Aged
Treatment Outcome
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents, Non-Steroidal; 89-57-6/Mesalamine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Time course of serum hepatitis C virus-RNA during chronic hepatitis C treatment accurately predicts ...
Next Document:  Lack of small intestinal ulcerogenecity of nitric oxide-releasing indomethacin, NCX-530, in rats.